研究单位：[1]Xiamen Amoytop Biotech Co., Ltd.[2]Tongji Hospital, Tongji Medical College Huazhou University of Science & Technology Wuhan, China[3]The First Affiliated Hospital of Xiamen University Xiamen, China[4]Zhejiang cancer hospital Zhejiang, China[5]Zhangzhou Municipal Hospital of Fujian Province Zhangzhou, Fujian, China, 363000[6]Shaaxi Provincial Tumor Hospital Xi'an, Shaanxi, China, 710061[7]Cancer Institute and Hospital, CAMS Beijing, China[8]Fujian cancer hospital Fuzhou, China[9]Fujian Medical University Union Hospital Fuzhou, China[10]Fuzhou General Hospital of Nanjing Military Command Fuzhou, China[11]The First Affiliated Hospital of Guangzhou Medical University Guangzhou, China[12]Shanghai Changzheng Hospital Shanghai, China[13]Shanghai Chest Hospital Shanghai, China
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
